Interferon alpha kinoid - Neovacs
Alternative Names: CKD-971; IFNalpha kinoid vaccine - Neovacs; IFNα-kinoidLatest Information Update: 05 Feb 2024
At a glance
- Originator Neovacs
- Developer Department Immunology of Diabetes at Hospital Cochin; Neovacs; sanofi pasteur
- Class Anti-inflammatories; Antihyperglycaemics; Interferons; Recombinant fusion proteins; Skin disorder therapies; Vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Dermatomyositis; Systemic lupus erythematosus
Highest Development Phases
- Phase II Dermatomyositis; Systemic lupus erythematosus
- No development reported Type 1 diabetes mellitus
- Discontinued HIV infections; Sjogren's syndrome
Most Recent Events
- 05 Feb 2024 Neovacs completes a phase IIb trial forSystemic Lupus Erythematosus in USA, Argentina, Belgium, Chile, Colombia, Croatia, France, Georgia, Germany, Italy, South Korea, Mexico, Moldova, Peru, Philippines, Poland, Russia, Switzerland, Taiwan, Thailand, Tunisia (IM, Injection) (NCT02665364) (EudraCT2015-001341-86) (Neovacs pipeline, January 2024)
- 13 Mar 2023 BioSense Global plans to file an IND application with the NMPA in China for phase IIb trial in Systemic lupus erythematosus
- 13 Mar 2023 BioSense Global plans a phase IIb trial in Systemic lupus erythematosus in China